Notably, treatment with the isoAb-IFNA169D fusion, which lacked loss of drug exposure with the multiple injection regimen, showed superior IFN activity in cDC1s, anti-tumor activity and survival compared to the CD11cAb-IFNA169D fusion (Supplementary Figures 5E, F). This evidence concerns the gene IFNA1 and neoplasm.